On the heels of basic research on the venom of Gila monsters in the preceding decades,1 exenatide secured the first US FDA approval in the class on April 28, 2005.2 While the prominent GLP-1 brand names are household names today, the class was off to a relatively slow start at first five years passed before it reached blockbuster status (US$1 billion (770 million) in sales), and another five went by before the first formal approval of a GLP-1 drug indicated for obesity became a reality.3 Last year saw sales for the class cross $50 billion and, with another 40% in revenue growth in store for 2025, the GLP-1 segment of the pharmaceutical industry is firmly in the rapid growth phase of the market, per Investment Bank Consensus
The future of metabolic healthcare may not just focus on managing symptoms
The prevalence of hypertension and pre-hypertension among adults (18 years and older) in Uganda was determined through a cross-sectional survey representing the entire nation (117)
[31] This is also the case for zinc fingers in which silver ions can replace zinc and form stable zinc/cysteine clusters with partial alpha helical structure
While repair and regeneration compose a topic in and of itself and worthy of another post, the point is that it would be desirable to seek new therapeutic agents that may interrupt the amplified oxidative/nitrosative cycle before necrosis is established in surviving hepatocytes so that they may recover, including through removal or repair of damaged mitochondria
Eli Lilly, which sells Zepbound and Mounjaro, just released a blockbuster Q2 this morning, beating Wall Street projections and raising its 2025 sales guidance